‘Dignity Therapy’ Innovators Aiming to Make Dying a More Positive, Fulfilling Experience

Page 11

Antioxidants, New Research: (1) In Head & Neck Cancer, Supplements Reduce RT Side Effects but Boost Recurrences; and (2) Data at American Chemical Society Meeting Finds Surprising Role for Coffee

Pages 38, 39

From World Conference on Breast Cancer: Surviving Husband Pleads: ‘Find Time to Include the Men in the Life of Women with Breast Cancer’

Page 30

BOOKS: Review of ‘Happiness in a Storm: Facing Illness and Embracing Life as a Healthy Survivor’ by Wendy Harpham, MD

Page 26

Deciding between Lumpectomy & Mastectomy: Study Finds the More a Patient Is Involved, the More Likely She Will Choose Mastectomy

Also: 3 Times as Many Surgeons Advised Breast Conservation than Mastectomy

Page 7

Advocacy InSight: Steep Commitment for Komen Breast Cancer 3-Day Walkers

Participants in the Walk must promise to raise a minimum of $2,100.

Page 15

SIMONE’S OncOpinion: Walker Percy: Physician & Homo Viator

Page 5

BREAST CANCER Decisions

- Reimbursement Policies Discourage Off-Label Drug Use .............. 8
- NCQA Report: Health Care Quality Improves, But Breast Cancer Screening Lags ................ 19
- Prostate Cancer: Significantly Less Biochemical Failure with High-Dose Conformal RT Compared with Conventional-Dose .......... 20
- A Different Look at the ‘Seed-and-Soil’ Hypothesis of Metastases ............ 28
- Patients Treated with Cetuximab May Require Magnesium Supplementation .......... 31
By Devon Schuyler

Many patients undergoing radiation therapy for cancer take antioxidant vitamin supplements in an effort to reduce side effects and improve treatment effectiveness. According to a new study of people with head and neck cancer, however, although this approach does appear to reduce side effects, it may also increase the risk of recurrence.

“This study is a warning that there could be adverse effects of antioxidant supplementation on radiation therapy,” said François Meyer, MD, Professor of Epidemiology at Laval University in Quebec, one of the study’s investigators. He hypothesized that the supplements might interfere with radiation’s ability to destroy cancerous cells.

The study, published in the August 20 issue of the Journal of Clinical Oncology (2005;24:5805-5813)—the lead investigator was Professor Isabelle Bairati, MD, PhD—is one of just a handful to examine the link between radiation and antioxidants; most studies of antioxidants and cancer treatment have looked at chemotherapy only.

The study included 533 Stage I or 2 head and neck cancer patients who were scheduled for treatment with radiation therapy. They had to be at least 18 years old and take no more than 50 IU of vitamin E and 6 mg of beta-carotene supplements a day in order to participate.

People in the supplement group tended to be less likely than those in the placebo group to experience Grade 3 or 4 side effects in all six sites during radiation treatment (19.2% vs 24.8%), but the difference was not statistically significant.

Dr. Meyer explained that in order to maximize the statistical power of the study, he and his colleagues looked at the odds of having an adverse effect score one grade higher (i.e., 1 instead of 0, 2 instead of 1, etc.) in each group compared with the other.

The researchers found that for the larynx alone, the odds of having an adverse effect score one grade higher during radiation treatment was 62% lower for people who took both vitamin E and beta-carotene than for those who took a placebo.

When all six sites were combined, adverse effects during radiation treatment also were less severe for people who took both vitamin E and beta-carotene. When patients took vitamin E alone, there was no reduction in adverse effects from radiation therapy.

The study also found a trend toward a higher rate of local recurrence in the supplement arm compared with the placebo arm. “Although this finding is not statistically significant, it’s sufficiently serious for us to see it as a warning,” Dr. Meyer said.

A separate analysis was conducted on the first 155 patients enrolled in the study because about half of them (77 patients) were the only ones who had received beta-carotene.

Dr. Meyer explained that most of these people received beta-carotene for at least the duration of the radiation therapy; the duration of supplementation ranged from 21 to 609 days.

There was a statistically significant reduction in the severity of radiation side effects, both during and at the end of radiation therapy. By contrast, the 380 patients who had received vitamin E alone did not experience any reduction in side effects.

Self-reported side effects from the supplements, such as yellowing of the skin, occurred in 42% of people in the supplement group and 16% of those in the placebo group.

In an accompanying editorial, Kevin Camphausen, MD, Deputy Chief of the Radiation Oncology Branch of the National Cancer Institute’s Center for Cancer Research, said, “The authors should be commended for running such a study and asking these questions. He said that the primary strength of this study was its large size, and the major weakness was the need to change the protocol partway through.

Harold E. Seifried, PhD, Program Director of the NCI’s Nutritional Sciences Research Group in the Division of Cancer Prevention, agreed that although the authors were right to change the study protocol, it was unfortunate that they needed to.

“Now the big question with this study is, did recurrence rates go up because patients had beta-carotene, because they didn’t have beta-carotene, or because they had vitamin E?”

He pointed out that beta-carotene might be a helpful supplement for people who don’t smoke, “but now no new study will touch it with a 10-foot pole, at least for some time.”

What to Tell Patients?

As for what to tell patients who ask about taking antioxidants during radiation treatment, Dr. Meyer said he would advise patients that any reduction in side effects is outweighed by a higher recurrence rate.

Dr. Camphausen said he also tells patients that they’re putting themselves at increased risk for a local recurrence if they insist on taking high-dose antioxidants. He recommends that patients eat a healthy diet and take a daily multivitamin that contains relatively low doses of antioxidants.

Based on the potential risks of antioxidants, Dr. Meyer advised against further studies of their use during radiation treatment for head and neck cancer. Instead, he suggested that follow-up studies examine the use of antioxidants after radiation therapy.

But Dr. Camphausen said that further studies were warranted even if... (continued on page 39)
American Chemical Society Annual Meeting

New Research on Antioxidants Shows Surprising Role for Coffee

By Peggy Eastman

WASHINGTON, DC—Recent studies from the American Institute for Cancer Research (AICR) and other groups have highlighted the importance of polyphenols, antioxidant compounds in fruits, vegetables, and tea, in reducing the risk of developing cancer. But, while groups such as the National Cancer Institute and the AICR have consistently advised Americans to eat more fruits and vegetables, Americans actually get most of their antioxidants from a surprising source: coffee.

That finding comes from research presented here at the American Chemical Society National Meeting by Joe A. Vinson, PhD, Professor of Chemistry at the University of Scranton (PA).

“I found out to my amazement that coffee was the number one source of antioxidants” in the US diet, he said, noting that both caffeinated and decaffeinated coffee brands seem to provide the same levels of antioxidants.

Joe A. Vinson, PhD: “I found to my amazement that coffee was the number one source of antioxidants in the US diet,” and both caffeinated and decaffeinated coffee brands seem to provide the same levels of antioxidants.

Dr. Vinson measured in milligrams the top 10 sources of antioxidants consumed on average in the US diet. Coffee was far and away the number one source at 1,299 mg per day. Black tea, the second source, was not even close at 294 mg per day.

Trailing tea in order of the amount of antioxidants generally consumed daily were bananas (76 mg), dry beans (72 mg), corn (48 mg), red wine (44 mg), lager beer (42 mg), apples (39 mg), tomatoes (32 mg), and potatoes (28 mg).

Dr. Vinson’s study was an in vitro test, and he emphasized in an American Chemical Society news briefing that there are limitations to this kind of study, including not knowing how much of the antioxidant compounds are actually being absorbed by the body.

He also was quick to say that coffee-loving Americans should not overdo their coffee consumption in hopes of being manipulated and changed to stop the tumor’s own cellular mechanics are unlike with toxic chemotherapy drugs—

In a separate study on mushrooms, Joy Dubost, a doctoral candidate in food science at Pennsylvania State University, reported on their work testing some 50 Japanese mushrooms to find an inhibitor of tyrosine kinase, which plays a key role in intracellular signaling and cancer proliferation. The team has discovered that a methanol extract from the fruiting body of *Polyporus multiplex*, the blue chanterelle mushroom, inhibited the activity of tyrosine kinase via the molecule polyozellin.

Benjamin Cravatt, PhD, reported on his work with activity-based protein profiling, an emerging proteomics technology that can detect the human proteins associated with breast cancer, including some not identified previously.

Dr. Cravatt combined activity-based protein profiling with the proteomics method multidimensional protein identification technology (MudPIT), which relies on mass spectrometry, to analyze protein pools in more detail. Dr. Cravatt said he hopes that using these two methods together could detect protein markers of disease that evade detection by other means.

Karen J. Brewer, PhD, Associate Professor of Inorganic Chemistry at Virginia Polytechnic Institute and State University, presented research on the synthesis and shedding of gangliosides, molecules in the membranes of most cells, could potentially serve as an alternative to traditional cancer treatments such as chemotherapy and radiation or as a nontoxic addition to these standard treatments, reported Stephan Ladisch, MD, Director of the Center for Cancer and Immunology Research at the Children’s Research Institute and Professor of Pediatrics and Biochemistry/Molecular Biology at George Washington University School of Medicine.

The synthesis and shedding of gangliosides by tumor cells (which produce gangliosides at a much more rapid rate than normal cells do) have been implicated in immune function, angiogenesis, and fibroblast proliferation. In work with an experimental mouse melanoma model, Dr. Ladisch administered a carbohydrate compound, OGT2378, which blocks the production of an enzyme cancer cells require to make gangliosides.

The tumors in OGT2378-treated mice were one-tenth the size of tumors in untreated mice, said Dr. Ladisch, who noted that with this approach—unlike with toxic chemotherapy drugs—the tumor’s own cellular mechanics are being manipulated and changed to stop its growth.

Researchers from Meiji Pharmaceutical University in Japan reported on their work testing some 50 Japanese mushrooms to find an inhibitor of tyrosine kinase, which plays a key role in intracellular signaling and cancer proliferation. The team has discovered that a methanol extract from the fruiting body of *Polyporus multiplex*, the blue chanterelle mushroom, inhibited the activity of tyrosine kinase via the molecule polyozellin.

There are limitations to this kind of study, including not knowing how much of the antioxidant compounds are actually being absorbed by the body.

In a world with some 8,000 polyphenols, it is impossible to know just what all of them do, Dr. Vinson said, noting that these compounds are designed to protect plants bombarded by ultraviolet radiation and other insults.

“There are thousands of polyphenols...we’ll never know them all. We just don’t know all the good things that come from these polyphenols yet. The proof is in vivo.”

Other Research Highlights

Highlights of other cancer-related research presented at the meeting followed.

- A novel investigational compound that interferes with the production of gangliosides, molecules in the membranes of most cells, could potentially serve as an alternative to traditional cancer treatments such as chemotherapy and radiation or as a nontoxic addition to these standard treatments, reported Stephan Ladisch, MD, Director of the Center for Cancer and Immunology Research at the Children’s Research Institute and Professor of Pediatrics and Biochemistry/Molecular Biology at George Washington University School of Medicine.

- The synthesis and shedding of gangliosides by tumor cells (which produce gangliosides at a much more rapid rate than normal cells do) have been implicated in immune function, angiogenesis, and fibroblast proliferation. In work with an experimental mouse melanoma model, Dr. Ladisch administered a carbohydrate compound, OGT2378, which blocks the production of an enzyme cancer cells require to make gangliosides.

- The tumors in OGT2378-treated mice were one-tenth the size of tumors in untreated mice, said Dr. Ladisch, who noted that with this approach—unlike with toxic chemotherapy drugs—the tumor’s own cellular mechanics are being manipulated and changed to stop its growth.

- Researchers from Meiji Pharmaceutical University in Japan reported on their work testing some 50 Japanese mushrooms to find an inhibitor of tyrosine kinase, which plays a key role in intracellular signaling and cancer proliferation. The team has discovered that a methanol extract from the fruiting body of *Polyporus multiplex*, the blue chanterelle mushroom, inhibited the activity of tyrosine kinase via the molecule polyozellin.

- Researchers from Meiji Pharmaceutical University in Japan reported on their work testing some 50 Japanese mushrooms to find an inhibitor of tyrosine kinase, which plays a key role in intracellular signaling and cancer proliferation. The team has discovered that a methanol extract from the fruiting body of *Polyporus multiplex*, the blue chanterelle mushroom, inhibited the activity of tyrosine kinase via the molecule polyozellin.

- Researchers from Meiji Pharmaceutical University in Japan reported on their work testing some 50 Japanese mushrooms to find an inhibitor of tyrosine kinase, which plays a key role in intracellular signaling and cancer proliferation. The team has discovered that a methanol extract from the fruiting body of *Polyporus multiplex*, the blue chanterelle mushroom, inhibited the activity of tyrosine kinase via the molecule polyozellin.